CTLA4 and neoplasm: Given the breakthrough advancements achieved by inhibition of CTLA-4 in several advanced tumor entities and the evidence on its functional relation to TIRC7, TIRC7 should be considered a potential new upstream molecule to be addressed therapeutically in CCA and other solid tumors.